U.K. keeps funding for clinical research sites flat through to 2022

Nick Paul Taylor The United Kingdom government is to pump £112 million ($ 160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar. FierceBiotech ...

Roche’s breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Carly Helfand Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly ...

Teva keeps the faith after another rebuke for Copaxone’s heir

Damian Garde Teva's $ 4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the ...

Novartis keeps apologizing for Diovan studies as it rakes in Diovan revenues

Eric Palmer Swiss drugmaker Novartis' situation with heart drug Diovan is like some kind of tragicomedy movie. The drugmaker has to keep apologizing for unethical studies of the ...

Roche’s new round of lung cancer data keeps spotlight on immunotherapies

John Carroll FierceBiotech News

LAT: Purdue keeps ‘risky’ OxyContin prescribers’ names private

Tracy Staton Purdue Pharma has a database of doctors who prescribe a lot of its painkiller OxyContin. On the face of it, that's not much of a statement, but in this case, the list ...

Gilead keeps lead in hep C race after rivals post key trial results

Ryan McBride After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS